Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 3 chart positions in 3 markets.
By chart position
- 🇦🇺AU · Life Sciences#1065K to 30K
- 🇩🇪DE · Life Sciences#1115K to 30K
- 🇳🇱NL · Life Sciences#1931K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
5.5K to 35K🎙 ~2x weekly·99 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
11K to 70K🇦🇺43%🇩🇪43%🇳🇱14% - Active Followers
Loyal subscribers who consistently listen
4.4K to 28K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Driving Project Execution Through Bioanalytical Continuity
Mar 28, 2026
1h 16m 22s
Special Guest: Scott Weir, University of Kansas Medical Center
Feb 28, 2026
1h 29m 15s
Happy New Year: Review of New Drug Approvals in 2025
Jan 28, 2026
1h 24m 23s
A New Ultra Sensitivity Approach for Protein Quantitation
Dec 28, 2025
1h 18m 51s
Conference Season 2025: Highlights and Impressions from AAPS and EBF Open Symposium
Nov 26, 2025
1h 08m 05s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 3/28/26 | Driving Project Execution Through Bioanalytical Continuity | On this latest episode of The Weekly Bioanalysis podcast, Dom and John dive into one of the most pressing challenges in modern bioanalysis: how to break down silos and drive better project execution through continuity across teams. Drawing from real-world experience, they explore how the industry has evolved from isolated workflows toward more integrated approaches, especially as complex therapeutics like ADCs and emerging platforms push traditional boundaries. The conversation highlights the... | 1h 16m 22s | ||||||
| 2/28/26 | Special Guest: Scott Weir, University of Kansas Medical Center | In the newest episode of "The Weekly Bioanalysis" podcast, our hosts, John and Dom welcome Scott Weir (Director, Institute for Advancing Medical Innovation at KU Medical Center) for a practical, behind-the-scenes look at how drug discovery and development can be executed in an academic setting—and what it takes to translate promising lab or bedside discoveries into real clinical programs. Scott breaks down the process through three clear “pillars” that guide early development: does the drug r... | 1h 29m 15s | ||||||
| 1/28/26 | Happy New Year: Review of New Drug Approvals in 2025 | In episode #97 of “The Weekly Bioanalysis” podcast, John and Dom focus on a review of 2025 drug approvals, revealing a surprisingly strong year for small molecules despite long-standing predictions of their decline. Of the 53 FDA approvals, 31 were small molecules, with additional complexity coming from ADCs and RNAi therapies, underscoring the continued importance of small-molecule development and analytics. The hosts also compare U.S. and European approvals, noting meaningful differences dr... | 1h 24m 23s | ||||||
| 12/28/25 | A New Ultra Sensitivity Approach for Protein Quantitation | John and Dom introduce guest Brad Nawa (Alamar Biosciences) to explain the NULISA™ platform, an ultra-sensitive platform for protein quantitation that aims to outperform earlier “ultra-sensitive” tools that often didn’t translate well in practice. Brad notes the platform is still antibody/content-driven, but differentiates itself by reducing background through a dual-capture purification step and a nucleic-acid barcode/ligation readout, enabling scalable multiplexing (currently ~256-plex, wit... | 1h 18m 51s | ||||||
| 11/26/25 | Conference Season 2025: Highlights and Impressions from AAPS and EBF Open Symposium | In the latest episode of the Weekly Bioanalysis podcast, Dom and John break down their biggest takeaways from the recent AAPS and EBF meetings, sharing what stood out across the scientific sessions, exhibition floors, and industry conversations. They discuss the major themes shaping bioanalysis right now, from emerging technologies to shifting regulatory expectations, and compare how each conference approached them. Our hosts also dive into evolving practices in biomarkers, immunogenicity, an... | 1h 08m 05s | ||||||
| 10/28/25 | Conference Season 2025: US, APAC, and European Bioanalysis Trade Shows | In this episode, hosts Dom and John welcome Jason Hannah, Director of Marketing at KCAS Bio, to discuss the company’s strategy for navigating the 2025 global conference season. With major events like AAPS PharmSci 360 in the U.S. and the European Bioanalysis Forum (EBF) in Barcelona on the horizon, Jason explains how KCAS approaches each with a structured, three-phase plan: pre-show planning, on-site activation, and post-show follow-up. He highlights the differences between large, trade show–... | 1h 13m 08s | ||||||
| 9/28/25 | Collaborating with Smaller, Scientifically-Driven Partners to Accelerate Drug Development (w/ Special Guest) | During episode #93 of The Weekly Bioanalysis, John and Dom welcome guest Chris Crean, founder/CEO of Xyzagen, who reflects on three decades in drug development and how the field has shifted from small molecules to today’s complex biologics, gene editing, and beyond. Chris explains how Xyzagen helps small, science-driven teams move faster by uniting early discovery “back-office” needs so studies are right-sized and decision-ready. He dives into modern PK design, showing how advances in LC-MS a... | 1h 29m 06s | ||||||
| 8/28/25 | GLP-1 Agonists – the Current State of Play and What’s Next (w/ Special Guest) | During episode #92 of The Weekly Bioanalysis, our hosts, John and Dom, dive into GLP-1 receptor agonists—originally developed for type 2 diabetes—and how their mechanisms (stimulating insulin, slowing gastric emptying, and reducing glucagon) also drive significant weight-loss effects. They discuss why native GLP-1 is too short-lived to be therapeutic and outline engineering strategies that extend half-life (e.g., fatty-acid albumin binding or Fc-fusion), walking through approved agents like e... | 1h 47m 16s | ||||||
| 7/28/25 | The “Grey Areas” of Bioanalysis: Drug Discovery, Biomarkers, Tissues & Technologies | In episode #91 of The Weekly Bioanalysis, John and Dom return to a two-person format to tackle the "gray areas" of bioanalysis, focusing on drug discovery, biomarkers, tissues, and emerging technologies. They discuss how traditional PK assay validation is highly standardized, but areas like early-stage discovery, biomarker qualification, and tissue analysis require more nuanced, fit-for-purpose approaches. A key theme is the need for flexibility and client collaboration, particularly when def... | 1h 25m 27s | ||||||
| 6/28/25 | Balancing Growth with Employee Experience, Part 2 - Special Guests, Maria Nelson & Julie Deane | In this episode of “The Weekly Bioanalysis” podcast, our hosts, Dominic Warrino and John Perkins, sit down with two key leaders shaping the company’s future — Maria Nelson, Chief Financial Officer, and Julie Deane, Chief People Officer — to discuss KCAS Bio’s strategy for balancing rapid growth with an exceptional employee experience. Building on the previous conversation with Jeff Goddard, this episode dives deeper into how KCAS Bio has evolved its people operations and operational planning.... | 1h 36m 58s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/28/25 | Balancing Growth with Employee Experience, Part 1 - Special Guest, Jeff Goddard | In Episode 89 of The Weekly Bioanalysis, hosts Dominic Warrino and John Perkins engage in a compelling conversation with special guest, Jeff Goddard, Senior Vice President of Corporate Development at KCAS Bio. The three delve into KCAS Bio's strategic growth, including the acquisition of France-based Active Biomarkers, which expanded the company's transatlantic presence. Jeff shares insights into the evolving landscape of bioanalytical services and how KCAS Bio is positioning itself to meet t... | 1h 36m 52s | ||||||
| 4/28/25 | Reflections on WRIB 2025 in New Orleans - With ALL the Guests!! | In Episode 88 of The Weekly Bioanalysis, hosts Dominic Warrino and John Perkins present a special WRIB 2025 recap featuring several KCAS Bio scientists who share firsthand insights from their presentations at the major bioanalytical conference. Dave Ambrose highlights KCAS Bio’s global harmonization of spectral flow cytometry instruments across sites in the U.S., France, and Australia, showcasing the industry’s first off-the-shelf spectral flow panel with impressively tight inter-site CVs. Je... | 1h 13m 07s | ||||||
| 3/28/25 | Evolution of SCIEX’s Partnership with Pharma in Drug Discovery & Development | In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company’s collaboration with KCAS Bio and introduces their high-throughput Echo technology, which uses acoustic ejection to improve speed and reduce carryover in early discovery assays. The ... | 50m 26s | ||||||
| 2/28/25 | Immunogenicity Discussion w/ Special Guest Cheikh Kane – What is a Lean ADA? | During episode 86 of KCAS Bio's "The Weekly Bioanalysis" podcast, our hosts Dom and John are joined by Dr Cheikh Kane, the Vice President of Biopharma Services at KCAS Bio, to discuss immunogenicity. They first define Immunogenicity; what it is and why it is tested, as well as the standard approach for ADA testing before answering the question of "What is a 'Lean' anti-drug antibody (ADA) approach, and when should it be employed?". Dr Kane brings his decades of experience and biopharmaceutica... | 1h 17m 16s | ||||||
| 1/28/25 | Patient-Centric Sampling: Beyond the Clinic and What it Means for Bioanalysis | Dom and John, the hosts of “The Weekly Bioanalysis”, recently returned from EBF in Barcelona where there was a session on Patient-centric Microsampling, which both of them founnd fascinating. This inspired both of them to decide it was high time to revisit this part of our industry. In spite of a few infamous setbacks caused by the dishonesty of a few bad actors within the industry a years ago, there has been a renewed interest in patient-centric sampling, and our hosts have invited one of th... | 1h 35m 35s | ||||||
| 12/28/24 | Small Molecule LC-MS Development and Evolving Approach to ADC Payloads | In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how the evolving role of LC-MS continues to shape the industry. Parmentier emphasizes the value of pre-validation in ensuring method robustness and shares lessons learned from develop... | 1h 32m 24s | ||||||
| 11/27/24 | Recap of the European Bioanalysis Forum Open Symposium | The 2024 tradeshow and conference season is finally coming to a close for the pharmaceutical and biotech industry, and our road-weary traveling hosts, Dom and John have returned from their final event, the 2024 European Bioanalysis Forum (EBF) Open Symposium in Barcelona, Spain. EBF was founded in 2006 at the initiative of 12 pharmaceutical companies. The goal was to create a platform for discussions around science, day-to-day procedures, business tools, technologies and - last but not least ... | 1h 17m 51s | ||||||
| 10/28/24 | Conference Season 2024: KCAS Bio’s Upcoming Exhibitions & Presentations | It’s conference season! This is a busy, busy time of the year for the entire industry, when everyone comes together from around the world to share, listen and discuss the changes and advancements taking place in the business and science of the pharma and biotech space. During this episode of “The Weekly Bioanalysis”, our hosts, Dom and John, go over all the places – around the world – where the KCAS Bio team will be taking part in exhibitions, panels and presentations. From Europe to Australi... | 1h 32m 03s | ||||||
| 9/28/24 | GLP-1 Analogue Bioanalysis: The Value of Complimentary Technologies | After such a great response to our recent episode on the topic, our hosts, Dom and John, revisit the topic of GLP-1 Analogue development and the role bioanalysis plays in this relatively new and popular topic. In the words of John, “Everyone else is talking about this; why shouldn’t we?” And wow, do they have a lot to say about it on this second pass at the advances being made in this ever-growing and ever-changing field. The guys talk about the latest developments in the GLP-1 Analogue space... | 1h 09m 35s | ||||||
| 8/28/24 | The Rapid Evolution of PCR Assays with Special Guest, Carrie Vyhlidal | Our hosts, Dom and John, are excited to welcome special guest, Carrie Vyhlidal, to discuss the topic of the 80th episode of “The Weekly Bioanalysis” podcast – The Rapid Evolution of PCR Assays. PCR (or Polymerase Chain Reaction) is like a copying machine for DNA. Scientists have found ways to measure the copies being made throughout the reactions, which is where they get their real-time, quantitative PCR (or qPCR). Carrie does a wonderful job of explaining not only why these advancements in t... | 1h 22m 46s | ||||||
| 7/28/24 |  One & Done Therapies: The Landscape of Gene Therapy for Conditions | The most recent episode of "The Weekly Bioanalysis" podcast is all about genes today! The topic was originally inspired by an article entitled "The Coming of Age of One-and-Done Therapies" which jumped out to both of our hosts, Dom and John, and had been on the back burner for a while for them to discuss. With KCAS Bio housing entire departments specializing in bioanalysis, and given the recent rise of similar topics in the news, this seemed like the right time for the guys to chat about it. ... | 1h 20m 09s | ||||||
| 6/28/24 | Offering Global Services: Latest News from Lyon and Melbourne | Dom has been globe-trotting lately, and he has come back to report in on his adventures with John, as they discuss our global services here at KCAS Bio. They talk about the updates and the latest news from Lyon and the rollout of our collaboration with Crux Laboratories in Melbourne. Most notable was Dom’s trip to Lyon and some of the excitement he experienced there (spoiler: it involves tear gas!!). Our two hosts also discuss the strategy and growth of both our Lyon site, and the new things ... | 1h 22m 04s | ||||||
| 5/28/24 | Non-GLP Studies from Early PK to Readiness for GLP Tox Studies | Dom and John welcome special guests, Habibi Goudarzi and Rochelle Burke to episode #77 of "The Weekly Bioanalysis", where they discuss the progression of bioanalytical needs for non-GLP Studies, from Early PK to readiness for GLP Tox Studies. These specialists from the KCAS Bio team begin with an introduction to all things non-GLP and LC-MS. From there, they discuss the general need for speed and the workflow they have established at KCAS Bio to facilitate rapid turnaround for studies, as wel... | 1h 30m 42s | ||||||
| 4/28/24 | GLP-1 Analogues: Blockbuster Drugs - Applications & Challenges | For episode #76 of "The Weekly Bioanalysis", Dom and John talk about the popular topic of GLP-1 Analogues - these series of recent blockbuster drugs with multiple applications, as well as some of their bioanalytical challenges. First, the guys go over a little bit of the mechanism of action of GLP-1's, then some of the rules around them and their initial diabetic treatments. They talk about the structures, and a little bit about how they are being used in weight loss (which, of course, is how... | 1h 25m 52s | ||||||
| 3/28/24 | Rebranding KCAS Bio: Next Steps to an Integrated Future | CEO of KCAS Bio, John Bucksath, joins Dom and John for a special 75th episode of “The Weekly Bioanalysis” podcast, and he is absolutely delighted to use the special episode to talk about the recent rebrand of KCAS to KCAS Bio! Mr Bucksath and our hosts discuss the reason the rebrand came about, the process our organization took, and some of the initial reactions our team have experienced from our first few outings with the new look and name. Join us as we introduce the new brand and point to ... | 1h 03m 05s | ||||||
Showing 25 of 99
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
3 placements across 3 markets.
Chart Positions
3 placements across 3 markets.